EFFICACY OF APPLICATION OF GENERIC IMATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
https://doi.org/10.29001/2073-8552-2017-32-2-36-41
Abstract
We have measured the residual concentration of imatinib in blood serum of patients, who have been treated with generic imatinib (Philachromin) in 24±3 hours after last administration. Patients, who have residual serum blood level of imatinib higher 900 ng/ml, have attained complete hematologic response (CHO) and major molecular response (MMR) more often, than patients, who have lower level (p<0.05). To compare treatment outcomes of original imatinib (Glivek) and generic imatinib (Philachromin) as initial therapy for CML, we have obtained no statistical differences in frequency of achieving of complete hematological response. The likelihood of achieving the complete cytogenetic response (CCR) is higher in patients, treated with original imatinib, than generic (89.5 и 73.3% respectively), as well as the frequency of achieving complete molecular response (78.9 and 33.3% respectively, с<0.01). Adverse effects of generic imatinib have been observed more often, than adverse effects of original imatinib (66.6 and 44.7% respectively).
About the Authors
A. S. Lyamkina
Novosibirsk State Medical University
Russian Federation
Russian Federation
A. I. Autenshlyus
Novosibirsk State Medical University
Russian Federation
Russian Federation
P. N. Miroshnikov
Novosibirsk State Medical University
Russian Federation
Russian Federation
A. V. Dubrovin
Novosibirsk State Medical University
Russian Federation
Russian Federation
References
1. Абдулкадыров К.М., Бессмельцев С.С., Рукавицын О.А. Хронический миелолейкоз. – СПб. : СпецЛит, 1998. – 464 с.
2. Куцев С.И. Генетический мониторинг таргетной терапии хронического миелоидного лейкоза : автореф. дисс. ... докт. мед. наук. – М., 2009. – 45 с.
3. Куцев С.И., Оксенюк О.С., Кравченко Е.Г. и др. Лекарственный мониторинг терапии хронического миелолейкоза иматинибом // Клиническая онкогематология. Фундаментальные исследования и клиническая практика. – 2010. – Т. 3, № 1. – С. 1–9.
4. Ломаия Э.Г., Зарицкий А.Ю. Нилотиниб – новый этап успеха в терапии хронического миелолейкоза. // Современная онкология, экстравыпуск. – С. 7–12.
5. Лорие С.С., Курова Е.С., Семочкин С.В., Туркина А.Г. и др. Эффективность и безопасность терапии иматиниб мезилатом (Гливеком) больных хроническим миелолейкозом в фазе акселерации // Вопросы гематологии/онкологии и иммунопатологии в педиатрии. – 2002. – Т. 1, № 2. – С. 66– 67.
6. Оксенюк О.С. Влияние концентрации иматиниба в плазме крови на эффективность терапии хронического миелоидного лейкоза // Автореферат диссертации на соискание ученой степени кандидата медицинских наук. – М., 2011. – 26 с.
7. Туркина А.Г., Хорошко Н.Д. Практические рекомендации по лечению больных хроническим миелолейкозом. – М., 2005. – С. 4–5.
8. Туркина А.Г., Хорошко Н.Д. Практические рекомендации по лечению больных хроническим миелолейкозом. – М., 2008. – С. 3–6.
9. Туркина А.Г., Хорошко Н.Д., Дружкова Г.А. и др. Эффективность терапии иматиниба мезилатом (Гливеком) в хронической фазе миелолейкоза // Терапевтический архив. – 2003. – Т. 75, № 8. – С. 62–67.
10. Туркина А.Г., Челышева Е.Ю. Цитогенетический и молекулярный ответ – ранние маркеры эффективности терапии Гливеком больных Ph+ хроническим миелолейкозом // Фарматека. – 2004. – № 18. – С. 48–54.
11. Хорошко Н.Д., Туркина А.Г., Кузнецов С.В. и др. Хронический миелолейкоз – успехи современного лечения и перспективы // Гематология и трансфузиология. – 2001. – № 4. – С. 7–12.
12. Allan N.C., Richards S.M., Sheperd P.C.A. et al. UK Medical Research Council randomised multicentre trial of interferon-α in chronic myeloid leukemia: improved survival irrespective of cytogenetic response // The Lancet. – 1995. – Vol. 345. – P. 1392–139.
13. Durig J., Rosenthal S., Elmaagacli A. et al. Biological effects of stroma-derived factor-1 alpha on normal and CML CD34+ haemopoietic cells // Leukemia. – 2000. – Vol. 14 (9). – P. 1652– 1660.
14. Fialkow P.J., Jacobson R.J., Papayannoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage // Am. J. Med. – 1997. – Vol. 63. – P. 125–130.
15. Gordon M.Y. Cellular and molecular mechanisms in chronic myeloid leukemia: biology and treatment // Brit. J. Haematol. – 1996. – Vol. 95. – P. 10–20.
16. Hasford J., Pfirrmann M., Hehlmann R. et al. A new prognostic score for survival of patients with chronic myeloid leukemia // Blood. – 2011. – Vol. 118 (3). – P. 686–92.
17. Sokal J.E., Cox E.B., Baccarani M. et al. // Blood. – 1984. – Vol. 63. – P. 789–799.
18. Kantarjian H.M., Cortes J.E., O,Brien S. et al. Imatinib mesylate therapy in newly diagnosed patients with Phyladelphya chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses // Blood. – 2003. – Vol. 101. – P. 97–100.
19. Kantarjian H.M., Hochhaus A., Cortes J. et al. Высокая эффективность и безопасность Нилотиниба у пациентов в хронической фазе хронического миелоидного лейкоза с резистентностью к иматинибу или непереносимостью иматиниба // Blood. – 2007. – Vol. 110. – 226a (abs.735).
20. Kantarjian H.M., Talpaz M., O,Brien S. et al. Imatinib mesylate for Phyladelphya chromosome-positive chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results // Clin. Cancer Res. – 2002. – Vol. 8. – P. 2177–2187.
21. Kloetzer W.S., Kurzrock R., Smith L. et al. The human cellular abl gene product in the chronic myelogenous leukemia cell line K-562 has associated tyrosine protein kinase activity // Virology. – 1985. – Vol. 140. – P. 230–238.
22. Kurzrock R., Kantarjian H.M., Druker B.J. et al. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics // Ann. Intern. Med. – 2003. – Vol. 138 (10). – P. 819–830.
23. Lugo T.G., Pendergast A.M., Muller A.J. et al. Tyrosin kinase activity and transformation potency of bcr-abl oncogene products // Science. – 1990. – Vol. 247. – P. 1079–1082.
24. McWhirter J.R., Wang J.Y. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins // Mol. Cell. Biol. – 1992. – Vol. 11. – P. 1553–1565.
25. Moravkovа et al. Polymerase Chain Reaction Analyses Should Be Used as a Basis for Clinical Decision Making in Patients With Chronic Myelogenous Leukemia // Blood. – 1999. – Vol. 94. – P. 3609–11.
26. O,Brien S.G., Guilhot F., Larson R.A. et al. Imatinib compared with interferon and low- dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia // N. Engl. J. Med. – 2003. – Vol. 348. – P. 994–1004.
27. O’Brien S., Guilhot F., Larson R. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic- phase chronic myeloid leukemia // N. Engl. J. Med. – 2003. – Vol. 348. – P. 994–1004.
28. Peled A., Hardan I., Trakhtenbrot L. et al. Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1 // Stem cells. – 2002. – Vol. 20 (3). – P. 259– 266.
29. Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukemia giemsa starting // Nature. – 1973. – Vol. 243. – P. 290–303.
30. Soverini S., Colarossi S., Gnani A. et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphiapositive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia // Clin. Cancer Res. – 2006. – Vol. 12 (24). – P. 7374–7379.
31. Steelman L.S., Pohnert S.C., Shelton J.G. et al. JAK/STAT, Raf/MEK/ERK, P13K/Akt and BCR-ABL in cell cycle progression and leukemogenesis // Leukemia. – 2004. – Vol. 18 (2). – P. 189– 218.
32. Van Etten R.A. Cycling, stressed-out and nervous of c-abl // Trend Cell. Biol. – 1999. – Vol. 9. – P. 179–186.
Review
For citations:
Lyamkina A.S., Autenshlyus A.I., Miroshnikov P.N., Dubrovin A.V. EFFICACY OF APPLICATION OF GENERIC IMATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA. Siberian Journal of Clinical and Experimental Medicine. 2017;32(2):36-41. (In Russ.) https://doi.org/10.29001/2073-8552-2017-32-2-36-41
Views:
371
.png)
Email this article 